CombiMatrix Launches Buccal Swab DNA Collection as Alternative to Blood Draws for Postnatal Genetic Testing
April 16 2015 - 08:00AM
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics
company specializing in DNA-based diagnostic services for prenatal,
postnatal, and pre-implantation genetic testing today announced the
availability of its new Buccal Swab DNA Collection system for the
CombiSNP Array for Pediatric Analysis microarray test effective May
1. The collection system uses a cheek swab in lieu of a blood draw,
which provides a more comfortable and convenient way to collect
samples from neonates and pediatric patients.
"Because of our High Touch service-oriented business model, we
are constantly looking for ways to improve our offering to
physicians and their patients," said Mark McDonough, President and
Chief Executive Officer of CombiMatrix. "The Buccal Swab DNA
Collection system is particularly helpful to those physicians who
do not have in-house phlebotomy services, and must send their
patients to a phlebotomy center. Now, the patient's DNA can be
collected in the physician's office without the need for a blood
draw. The Buccal Swab DNA Collection system saves patients' time,
and offers a painless alternative to a blood draw, which is
particularly useful when samples need to be collected from neonatal
and pediatric patients. We are excited about offering this option
and believe that it will open up new testing avenues for
office-based physicians who see patients that require microarray
testing. This is largely an untapped market for us until now."
Sample collection is very easy to perform: simply swab both
cheeks, cap the tube, and then invert it to mix the DNA with the
special preservative solution. Samples are then sent to the
Company's testing laboratory in Irvine, California, where the DNA
is extracted and run on the same test platform as the blood
samples.
About CombiMatrix Corporation
CombiMatrix Corporation provides valuable molecular diagnostic
solutions and comprehensive clinical support for the highest
quality of care – specializing in pre-implantation genetic
screening, miscarriage analysis, prenatal and pediatric healthcare.
CombiMatrix offers comprehensive testing services for the detection
of abnormalities of genes at the DNA level beyond what can be
identified through traditional technologies. The Company performs
genetic testing utilizing microarray, FISH, PCR and G-Band
chromosome analyses. Additional information about CombiMatrix is
available at www.combimatrix.com or by calling 1-800-710-0624.
Safe Harbor Statement under the Private Securities
Litigation Reform Act of 1995
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These statements are
based upon our current expectations, speak only as of the date
hereof and are subject to change. All statements, other than
statements of historical fact included in this press release, are
forward-looking statements. Forward-looking statements can often be
identified by words such as "anticipates," "expects," "intends,"
"plans," "goal," "predicts," "believes," "seeks," "estimates,"
"may," "will," "should," "would," "could," "potential," "continue,"
"ongoing," "objective," similar expressions, and variations or
negatives of these words. These forward-looking statements are not
guarantees of future results and are subject to risks,
uncertainties and assumptions that could cause our actual results
to differ materially and adversely from those expressed in any
forward-looking statement. The risks and uncertainties referred to
above include, but are not limited to: market acceptance of our
buccal swab DNA collection system by physicians; our ability to
successfully expand the base of our customers and strategic
partners, add to the menu of our diagnostic tests in both of our
primary markets, develop and introduce new tests and related
reports, optimize the reimbursements received for our testing
services, and increase operating margins by improving overall
productivity and expanding sales volumes; our ability to
successfully accelerate sales, steadily increase the size of our
customer rosters; our ability to attract and retain a qualified
sales force; rapid technological change in our markets; changes in
demand for our future services; legislative, regulatory and
competitive developments; general economic conditions; and various
other factors. Further information on potential factors that could
affect our financial results is included in our Annual Report on
Form 10-K, Quarterly Reports of Form 10-Q, and in other filings
with the Securities and Exchange Commission. We undertake no
obligation to revise or update publicly any forward-looking
statements for any reason, except as required by law.
CONTACT: Company Contact:
Mark McDonough
President & CEO, CombiMatrix Corporation
(949) 753-0624
Media Contact:
David Schull or Lena Evans
Russo Partners LLC
(212) 845-4271
david.schull@russopartnersllc.com
lena.evans@russopartnersllc.com
Investor Contact:
Robert Flamm, Ph.D.
Russo Partners, LLC
(212) 845-4226
robert.flamm@russopartnersllc.com
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Historical Stock Chart
From Mar 2023 to Mar 2024